This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Memorial Sloan Kettering Cancer Center. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Michel W J Sadelain: Innovator in T Cell Therapy
Introduction
Michel W J Sadelain is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of immunotherapy, particularly in the development of T cell therapies. With a total of 2 patents, Sadelain's work focuses on innovative methods to enhance the efficacy of T cell treatments for various diseases.
Latest Patents
Sadelain's latest patents include groundbreaking inventions related to transgenic T cells and chimeric antigen receptor (CAR) T cell compositions. One of his notable inventions provides a T cell wherein one or more therapeutic transgenes is integrated within the genome of the cell. This integration allows for the expression of the transgene to be controlled by an endogenous promoter of the T cell. Additionally, he has developed methods for creating and utilizing such cells to treat subjects with T cell therapy. Another significant aspect of his work involves a T cell where a recombinant nucleic acid sequence encoding a CAR is integrated at a specific site within the genome. This integration ensures that the CAR is expressed on the cell surface while reducing or preventing the expression of a functional T cell receptor complex. These innovations are pivotal in advancing CAR therapy.
Career Highlights
Michel W J Sadelain is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to push the boundaries of cancer treatment through his research and inventions. His work has garnered attention and respect within the scientific community, contributing to the advancement of therapeutic options for patients.
Collaborations
Sadelain collaborates with esteemed colleagues, including Justin Gabriel, Andre Francois Eyquem, and Jorge Mansilla-Soto. These partnerships enhance the research and development of innovative therapies in the field of cancer treatment.
Conclusion
Michel W J Sadelain is a leading figure in the realm of T cell therapy, with a focus on innovative approaches that have the potential to transform cancer treatment. His contributions through patents and collaborations continue to shape the future of immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile